Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
SALT LAKE CITY— Sera Prognostics , Inc. (NASDAQ:SERA), a $146 million market cap company currently trading at $4.32, has seen recent insider activity with the company’s Chief Scientific Officer, John J. Boniface, executing transactions involving Class A Common Stock. According to a Form 4 filing, Boniface sold 2,044 shares on March 6, 2025, at a weighted average price of $4.16 per share, amounting to a total of $8,503. InvestingPro analysis shows the stock has declined over 54% in the past year, though the company maintains a strong balance sheet with more cash than debt.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs), as mandated by Sera Prognostics’ policy. This transaction was not a discretionary sale by Boniface. With the company’s next earnings report scheduled for March 19, 2025, InvestingPro subscribers can access comprehensive insider trading analysis and 8 additional key insights about SERA’s financial health and market position.
In addition to the sale, Boniface acquired 47,010 shares through restricted stock units on March 5, 2025. These RSUs are set to vest over four years, contingent upon continued service with the company. Additionally, Boniface was granted stock options for 67,810 shares, also vesting over a four-year period.
Following these transactions, Boniface’s direct ownership stands at 170,850 shares of Sera Prognostics.
In other recent news, Sera Prognostics has terminated its $50 million "at-the-market" stock offering, as detailed in a recent SEC filing. The company had not sold any shares under this arrangement, and the decision requires a new prospectus supplement for future equity sales. Meanwhile, Sera Prognostics has also launched a public offering of its Class A common stock and pre-funded warrants, managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets. The proceeds from this offering are intended to support U.S. commercial expansion, EU growth, FDA approval efforts for its PreTRM test, and other corporate purposes. Additionally, the Society for Maternal Fetal Medicine has published an abstract with topline results from Sera Prognostics’ PRIME study, which focuses on improving neonatal outcomes. These results will be presented in detail at the SMFM 2025 Pregnancy Meeting, with a subsequent conference call and webcast scheduled for February 6, 2025. These developments highlight the company’s ongoing research efforts and strategic plans for growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.